Program
silodosin
Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.
Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.
Drug pageSilodosin: every studyMany companies study it; this page follows only the 17 they lead. All 40 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 60 open or running | phase 3since Sep 14, 2005 | Sep 14, 2005 | none ahead |
| JW Pharmaceuticalits history only | 50 open or running | phase 4since Oct 25, 2010 | Oct 25, 2010 | none ahead |
| Kissei Pharmaceuticalits history only | 20 open or running | phase 2since Oct 15, 2010 | Oct 15, 2010 | none ahead |
| RECORDATI GROUPits history only | 20 open or running | phase 4since Dec 21, 2012 | Aug 2, 2006 | none ahead |
| Shanghai Huilun Pharmaceuticalits history only | 10 open or running | phase 4since Aug 14, 2025 | Aug 14, 2025 | none ahead |
| Xintian Pharmaceutical | 10 open or running | phase 4since Sep 19, 2022 | Sep 19, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Xintian Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2022First study: phase 4 study in Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsFirst studyNCT05551221 · 110 enrolled · China
TargetBeta
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on ADRA1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
The one study Xintian Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05551221Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms · China | 4 | Completed | Sep 10, 2024 | 110 |
How it is read
Names in the registry
- “Silodosin”, 12 entries
- “silodosin”, 5 entries
- “KSO-0400”, 2 entries
- “Silodosin Capsules”, 1 entry
- “Silodosin 8 mg”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 9 studies
- Nocturia, 2 studies
- Lower Urinary Tract Symptoms, 1 study
- Ureteral Calculi, 1 study
- Ureterolithiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.